Hypoxia is associated with a number of diseases including arthritis, diabetic retinopathy, ischemic heart disease, stroke and solid tumors.
Hypoxia is associated with a number of diseases including arthritis, diabetic retinopathy, ischemic heart disease, stroke and solid tumors. 1, 2 The presence of hypoxia in solid tumors is a major impediment for successful therapy as it is associated with resistance to radiation and chemotherapies and a predisposition to increased metastasis. 3 Therefore, it is important to develop novel therapeutic strategies which can specifically target hypoxic areas of tumors.
Hypoxic conditions initiate a cascade of physiological responses and lead to the induction of genes involved in glycolysis, erythropoiesis and angiogenesis. 4 The HIF-1 transcription factor mediates transcriptional responses to hypoxia by binding to a highly conserved cis-acting HRE present within target genes, such as those encoding EPO and VEGF. 5, 6 The use of the HIF-1/HRE system of gene regulation, which is active only under hypoxic conditions or as a result of genetic alterations during cell transformation, 1, 4 can be utilized as a mechanism to target expression of therapeutic genes specifically. HREs
expression vectors using HREs derived from the human vascular endothelial growth factor (VEGF) and erythropoietin (EPO) genes. We measured the ability of these constructs to express the luciferase and LacZ/␤-galactosidase (␤-gal) reporter genes bidirectionally under normoxic (21% O
) versus hypoxic (1, 3, 5, derived from different genes confer hypoxic inducibility to heterologous promoters (both viral and tissue specific) in various cell types in vitro and in vivo. [7] [8] [9] [10] [11] [12] Most important with respect to gene therapy delivery is the finding that HREs retain hypoxia/HIF-specific induction of gene expression when present in circular plasmids and retro-and adenoviral vector systems. 13, 14 While these studies have laid the foundation for hypoxia-regulated control of therapeutic gene expression, these first-generation vectors are limited in several respects. First, most of the HRE-regulated vectors designed to date display only modest induction (less than 10-fold) under hypoxia. Recent data suggest that this limitation can be overcome by the use of multimerized HREs coupled to minimal viral promoters. 9, 10 Second, these vectors are designed to direct single therapeutic gene expression. One strategy utilizes expression of tumor suppressor genes which exhibit cell intrinsic effects such as growth arrest or apoptosis. 15 The major drawbacks associated with this strategy are that: (1) therapeutic gene expression will only occur in hypoxic tumor cells while sparing normoxic tumor cells; and (2) efficacy relies on gene transfer to 100% of the hypoxic tumor cells. The second approach tried to overcome these limitations by the use of hypoxia-regulated suicide genes which rely on a 'bystander effect' to kill normoxic tumor cells. 7, 12 While this approach is more likely to generate a microenvironment that is hostile to tumor growth even at low gene transduction levels, its current therapeutic efficacy is low. While the specific reasons for this are being explored, it is reasonable to assume that a suicide gene therapy strategy will be most useful when combined with other antitumor approaches. In addition, the high levels of genetic instability in tumor cells produce genetic heterogeneity within a tumor mass and between tumors, which allows tumor cells to become rapidly resistant to single therapeutic strategies. Therefore, it is important to develop new vector systems that can deliver simultaneously two or more antitumoral agents that will act synergistically and reduce the chance for tumor resistance.
There are approximately 30 genes which are regulated by hypoxia and the HRE within many of these genes has been identified. All of these are candidates to be used in expression vectors for gene delivery to hypoxic areas in a variety of pathologies. It is currently unknown which HRE will confer optimal regulation and induction of gene expression at desired levels within the hypoxic regions of diseased tissues, such as the tumor microenvironment. It is also unknown whether any of these elements will function bidirectionally. In this study we examined the potential use of the HREs present within the 3Ј-flanking region of the EPO gene and the 5Ј-flanking region of the VEGF gene. 16, 17 We designed a large series of novel mammalian expression plasmids that contain hypoxia/HIF-responsive promoters which function bidirectionally to co-regulate the activity of two genes ( Figure 1 ). We demonstrate that HREs from the EPO and VEGF genes can bidirectionally co-regulate the expression of two independent promoters, suggesting that these elements function as classical enhancer elements. Moreover, we demonstrate that these promoters exhibit selective induction under hypoxia and provide variable levels of induction dependent upon HRE copy number. This versatile vector panel will be an invaluable tool for studies aimed at targeting dual therapy through variable gene expression specifically to areas of hypoxia within diseased tissues or in transformed cells which exhibit constitutive HIF-1 activity.
To generate bidirectional hypoxia/HIF-responsive promoters, the pBI (TET) and pBI-GL (TET) mammalian expression vectors 19 were modified such that the tetresponsive elements (TET) were removed and replaced with HREs derived from the 3Ј-flanking region of the EPO gene or the 5Ј-flanking region of the VEGF gene ( Figure 1) . 16, 17 We chose these HREs for our studies because they have been extensively characterized. These HREs are less than 50 bp in length and contain a highly conserved HIF-1 binding site and other gene-unique cisacting sequences that are functionally essential for hypoxic induction. Oligonucleotides spanning the EPO and VEGF HREs were synthesized, concatemerized and then cloned in tandem (head-to-tail orientation) into pBI and pBI-GL vectors, where the TET enhancer was removed. The resulting pBI-GL HRE plasmids containing one to six tandem copies of the VEGF or EPO HRE in both the 5Ј and 3Ј orientations (23 constructs in total) were then utilized to characterize the hypoxia-responsive promoters as described below. The pBI HRE plasmids can be used for the cloning and hypoxia/HIF-dependent expression of two genes of interest.
The pBI-GL VEGF HRE constructs were analyzed for the ability to bidirectionally induce the luciferase and LacZ/␤-gal reporter genes expression in response to hypoxia. The influence of HRE copy number and orientation on the basal activity and hypoxia-specific induction of the reporter genes was also examined. The LN229 human glioblastoma cell line was transiently transfected with the constructs and then exposed to normoxic (20.8%) or hypoxic (1%) oxygen levels for 48 h. Enzymatic activities were measured by chemiluminescent assays and normalized to total protein in the cellular extracts. The original pBI (TET) and pBI-GL (TET) plasmids were used as negative controls for these experiments.
The VEGF HRE induced bidirectional reporter gene expression under hypoxic conditions ( Figure 2 ). Seven plasmids (V3L, V5L, V6L, V3R, V4R, V5R, V6R), which contain three to six tandem copies of the VEGF HRE, achieved induction levels for luciferase of seven-(V3L) to 41-(V4R) fold and for ␤-gal of 32-(V3L) to 91-(V6L) fold in response to hypoxia. Importantly, the bidirectional induction of the reporter genes was not dependent upon the orientation of the tandem copies as high induction was exhibited when the tandem copies were facing in both the 5Ј and 3Ј directions (L versus R in the construct name). Finally, reporter gene expression of these constructs under normoxia was minimal and similar to that seen with the pBI-GL (TET) negative control. pBI-GL constructs containing only one or two copies of the VEGF HRE exhibited a much lower level of reporter gene induction in response to hypoxia, only one-to three-fold for luciferase and two-to 12-fold for ␤-gal.
The pBI-GL EPO HRE constructs were similarly analyzed under 1% oxygen levels in LN229 cells. The EPO HRE induced bidirectional reporter gene expression under hypoxic conditions (Figure 3 ). However, in contrast to the VEGF HRE constructs, only two of the plasmids (E3L and E6L) exhibited a robust bidirectional induction of the reporter genes in response to hypoxia (15-and 31-fold, for luciferase and 143-and 77-fold for ␤-gal, respectively). Background activity under normoxia was minimal and similar to that seen with the pBI-GL (TET) negative control. The remaining constructs exhibited either a low level of reporter gene induction (one-to 12-fold) in response to hypoxia (E1L, E2L, E1R, E2R, E3R, E4R, E5R, E6R) or the reporter gene activity under normoxic conditions was significantly greater (P Ͻ 0.038) than the pBI-GL (TET) control vector (E4L, E5L, E4R, E5R, E6R).
To confirm and extend these results, we selected eight constructs (E3L, E6L, V5L, V6L, V3R, V4R, V5R, V6R) for testing in other cancer cell lines (Table 2 and data not shown). These constructs exhibited the lowest levels of reporter gene activity under normoxia and the highest bidirectional induction of reporter gene activity in response to hypoxia in LN229 cells. Simultaneous analysis of these eight constructs enabled us to compare the basal activity and hypoxic-induction capability of the VEGF and EPO HREs and to determine which response element confers optimal regulation in cancer cell lines. All eight pBI-GL HRE constructs exhibited high levels of reporter gene activity in response to hypoxia (1% O 2 ) in both the U251MG and U138MG glioma cells (Table 2) . Background expression under normoxia was minimal 19 and similar to that seen with the pBI-GL (TET) control vector. These eight constructs gave similar results in the MDA-MD-468 breast, DU145 prostate and DAOY medulloblastoma cell lines (data not shown), demonstrating that these expression vectors function in a heterogenous set of cancer cell lines. To compare the level of reporter gene activity obtained from the HRE promoter under hypoxia (1% O 2 ) with that of a constitutive promoter (CMV IE) we transfected U251MG cells with pBI-GL V6R, pBI-GL E6L, CMV-luciferase and CMV-LacZ/␤-gal. The reporter gene activity of the HRE promoters after hypoxic induction was reduced by 4.7-and 9.0-fold for luciferase
were modified to generate a series of bidirectional hypoxia-responsive expression vectors (pBI HRE and pBI-GL HRE). The pBI (TET) and pBI-GL (TET) vectors contain a bidirectional tetracycline (tet) responsive enhancer which is
Gene Therapy activity and 2.6-and 3.8-fold for ␤-gal activity in comparison with the CMV IE promoters (data not shown).
In contrast to the cell culture environment, we anticipate that in vivo, particularly within a tumor mass, there will be a gradient of oxygen. Hence, it is important to determine the range of partial oxygen pressure in which these HRE promoters will be active. Therefore, we examined the bidirectional promoter activity of these eight constructs under normoxic (20.8%) and variable hypoxic (1%, 3%, 5%, and 10%) conditions in transiently transfected U138MG cells as described above. The level of reporter gene activation by the VEGF and EPO HRE pro- moters was a function of partial oxygen pressure ( Figure  4) , with exponential activation at oxygen concentrations below 5%. Moreover, there was no obvious difference in the response of the VEGF versus EPO HRE promoters to the variable oxygen conditions. In summary, our results show that we have generated a large set of novel mammalian expression plasmids that contain HRE promoters with one to six tandem copies of the VEGF or EPO HRE and which function bidirectionally to co-regulate the activity of two genes. Nine of the 23 constructs (two EPO and seven VEGF) displayed moderate to high levels of bidirectional reporter gene expression in response to hypoxia (1% O 2 ), while maintaining minimal reporter gene expression under normoxia (21% O 2 ) in cell lines derived from glioma, medulloblastoma, breast and prostate cancers. Moreover, we found that the level of reporter gene activation was a function of O 2 concentration and increased exponentially at O 2 levels below 5%.
Figure 2 Bidirectional hypoxic induction of the VEGF-HRE promoter in LN229 human glioblastoma cells. The pBI-GL VEGF-HRE constructs were examined for their ability to bidirectionally express the luciferase (A1 and B1) and ␤-gal (A2 and B2) reporter genes in response to 1% O 2 in transiently transfected LN229 cells. The pBI-GL (TET) and pBI TET (data not shown) plasmids were used as negative controls. V1L refers to the pBI-GL VEGF-HRE plasmid which contains one copy of the HRE element facing in the left direction. Fold induction and error bars (standard deviation) are indicated. Methods: Each construct was transiently transfected in triplicate wells using GenePORTER transfection reagent (Gene Therapy
Only the pBI-GL E3L and E6L HRE plasmids exhibited both a strong bidirectional reporter gene induction under hypoxia and a low level of reporter gene activity under normoxia. The high fold induction levels of the E3L construct were due to low expression under normoxia, rather than strong expression in hypoxia. This pattern of expression may prove beneficial in a setting where the expression of low levels of a therapeutic gene in normoxic cells may be extremely toxic. The activity of the E6L HRE construct was similar to that of several VEGF HRE constructs (Table 2 and data not shown). The remaining 10 EPO constructs exhibited low levels of hypoxic induction or displayed high levels of activity under normoxia. The number of HREs could have an effect on basal or inducible transcriptional activation in several ways. One possibility is that the alignment of these elements with the turns of the double helix influences heterodimeric protein-DNA binding. Furthermore, beside a HIF-1 binding site, HREs contain other cis-acting sequences that are functionally essential for hypoxia-specific induction. It is possible that LN229 cells may express low levels of critical cofactor(s) needed for tight hypoxiainducible regulation of the EPO HRE and that these might be sensitive to three-dimensional alignment of the HREs on the double helix as well. These data substantiate previous findings of others and suggest that the observed low inducibility and high normoxic background Gene Therapy observed with some EPO HRE constructs are associated with the HRE rather than a particular cell type or linked minimal promoter. 8, 15, 18 Given the restrictions associated with the EPO HRE, it appears that this element may not be the best candidate for the design of a general gene therapy vector to target the hypoxic component of many tumor types.
Currently available data about the use of the VEGF HRE as a means to drive hypoxia/HIF-specific expression of a target gene are limited. The mouse VEGF promoter region encompassing the HRE results in a low level (two-to three-fold) of induction in response to hypoxia in mouse Lewis lung carcinoma A11 cells. 12 Similarly, we found that pBI-GL constructs containing only one or two copies of the human VEGF HRE exhibited a low level (Ͻ12-fold) of reporter gene induction in response to hypoxia. The use of concatemerized copies (three, five and ten) of the human VEGF HRE have demonstrated high levels of hypoxia-specific induction in the HT1080 fibrosarcoma and Hep G2 hepatocellular human cell lines. 10, 18 Our studies build upon and expand on these previous studies. We show that the use of concate- The indicated pBI-GL VEGF-or EPO-HRE constructs were examined for their ability to bidirectionally express the luciferase and ␤-gal reporter genes in response to 21% and 1% O 2 in U251MG and U138MG cells as described in the legend to merized VEGF HREs (>three copies) appear optimal in conferring high levels of hypoxia-specific gene induction in six different cell lines representing four tissues types (glial, primitive neuroectodermal, prostate and breast). We further show that induction levels increase abruptly when the number of HRE copies present is greater than two and that induction levels are further increased in a non-linear fashion when HRE copies are gradually increased (to three, four, five and six copies). We also demonstrate that the bidirectional induction of the reporter genes was not dependent upon the orientation of the tandem copies as high induction was exhibited when the tandem copies were facing in both the 5Ј and 3Ј directions. Moreover, the VEGF HRE functions upstream of several viral minimal promoters (CMV (this study), E1b, and SV40 10, 12, 18 ). Finally, these HRE elements function in a wide range of human cell types. These combined results strongly suggest that concatemerized VEGF HREs are ideal candidates in the development of hypoxia/HIF-regulated gene delivery vectors.
The vector series described in this study can be utilized in the design of gene therapy vectors to specifically target the co-expression of two independent therapeutic genes in a variety of pathological conditions, where variable gene expression driven by hypoxia or an activated HIF-1/HRE pathway 1,4 might be of therapeutic value. This is particularly attractive for cancer treatment as hypoxia is an abnormal physiological condition that exists in all solid tumors regardless of their origin, location or biologic and genetic heterogeneity. Therefore, hypoxia can be utilized to specifically target therapy to tumors while sparing normal cells which are well-oxygenated. Furthermore, the bidirectional gene expression cassette is of a size compatible with cloning into viral vector systems, including retro-and adenoviral, thus providing added versatility in the field of therapeutic gene delivery. Moreover, the number of genes expressed can conceptually be increased to four if internal ribosomal entry sites (IRES) were used to express two genes per transcription unit.
